Inspire Medical Systems, Inc. Forecast, price target & analysts
Inspire Medical Systems, Inc. Target price 2025 - Analyst rating & recommendation
Inspire Medical Systems, Inc. Classifications & Recommendation:
Inspire Medical Systems, Inc. Price Target
| Target Price | $235.88 |
| Price | $184.02 |
| Potential |
28.18%
register free of charge
|
| Number of Estimates | 16 |
|
16 Analysts have issued a price target Inspire Medical Systems, Inc. 2026 .
The average Inspire Medical Systems, Inc. target price is $235.88.
This is
28.18%
register free of charge
$280.00
52.16%
register free of charge
$190.00
3.25%
register free of charge
|
|
| A rating was issued by 20 analysts: 15 Analysts recommend Inspire Medical Systems, Inc. to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Inspire Medical Systems, Inc. stock has an average upside potential 2026 of
28.18%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 802.80 | 949.61 |
| 28.49% | 18.29% | |
| EBITDA Margin | 5.31% | 19.82% |
| 188.64% | 273.25% | |
| Net Margin | 6.48% | 6.80% |
| 289.16% | 4.89% |
18 Analysts have issued a sales forecast Inspire Medical Systems, Inc. 2025 . The average Inspire Medical Systems, Inc. sales estimate is
This results in the following potential growth metrics:
10 Analysts have issued an Inspire Medical Systems, Inc. EBITDA forecast 2025. The average Inspire Medical Systems, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Inspire Medical Systems, Inc. Analysts have issued a net profit forecast 2025. The average Inspire Medical Systems, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.75 | 2.17 |
| 343.06% | 24.00% | |
| P/E | 84.72 | |
| EV/Sales | 5.31 |
8 Analysts have issued a Inspire Medical Systems, Inc. forecast for earnings per share. The average Inspire Medical Systems, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Inspire Medical Systems, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Inspire Medical Systems, Inc....
Current Inspire Medical Systems, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wells Fargo | Locked ➜ Locked | Locked | Feb 11 2025 |
| Baird | Locked ➜ Locked | Locked | Feb 11 2025 |
| RBC Capital | Locked ➜ Locked | Locked | Feb 11 2025 |
| Morgan Stanley | Locked ➜ Locked | Locked | Feb 11 2025 |
| Truist Securities | Locked ➜ Locked | Locked | Feb 11 2025 |
| Piper Sandler | Locked ➜ Locked | Locked | Feb 10 2025 |
| Keybanc | Locked ➜ Locked | Locked | Jan 24 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wells Fargo: Locked ➜ Locked
|
Feb 11 2025 |
|
Locked
Baird: Locked ➜ Locked
|
Feb 11 2025 |
|
Locked
RBC Capital: Locked ➜ Locked
|
Feb 11 2025 |
|
Locked
Morgan Stanley: Locked ➜ Locked
|
Feb 11 2025 |
|
Locked
Truist Securities: Locked ➜ Locked
|
Feb 11 2025 |
|
Locked
Piper Sandler: Locked ➜ Locked
|
Feb 10 2025 |
|
Locked
Keybanc: Locked ➜ Locked
|
Jan 24 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
